Journal of Gastric Cancer

The Korean Gastric Cancer Association (대한위암학회)
권호 표지
DOI QR코드

DOI QR Code

Hypercalcemia as Initial Presentation of Metastatic Adenocarcinoma of Gastric Origin: A Case Report and Review of the Literature

  • Kumar, Mehandar (Department of Hematology-Oncology, Saint Joseph's Regional Medical Center at New York Medical College) ;
  • Kumar, Abhishek (Department of Hematology-Oncology, Saint Joseph's Regional Medical Center at New York Medical College) ;
  • Kumar, Vinod (Department of Hematology-Oncology, Saint Joseph's Regional Medical Center at New York Medical College) ;
  • Kaur, Supreet (Department of Hematology-Oncology, Saint Joseph's Regional Medical Center at New York Medical College) ;
  • Maroules, Michael (Department of Hematology-Oncology, Saint Joseph's Regional Medical Center at New York Medical College)
  • Received : 2016.04.27
  • Accepted : 2016.06.15
  • Published : 2016.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Hypercalcemia of malignancy due to metastatic gastric adenocarcinoma is extremely rare; in fact, to the best of our knowledge, only three case reports of hypercalcemia associated with metastatic gastric adenocarcinoma have been published in the literature to date. Herein, we report a rare case involving a 61-year-old African-American female who had hypercalcemia at initial presentation and who was later diagnosed with poorly differentiated gastric adenocarcinoma with extensive liver metastases, without bone involvement. She was found to have elevated parathyroid hormone-related peptide and normal parathyroid hormone levels. Despite aggressive treatment, she died within a few months of diagnosis.

Keywords

References

  1. Vassilopoulou-Sellin R, Newman BM, Taylor SH, Guinee VF. Incidence of hypercalcemia in patients with malignancy referred to a comprehensive cancer center. Cancer 1993;71:1309-1312. https://doi.org/10.1002/1097-0142(19930215)71:4<1309::AID-CNCR2820710423>3.0.CO;2-M
  2. Ralston SH, Gallacher SJ, Patel U, Campbell J, Boyle IT. Cancer-associated hypercalcemia: morbidity and mortality. Clinical experience in 126 treated patients. Ann Intern Med 1990;112:499-504. https://doi.org/10.7326/0003-4819-112-7-499
  3. Stewart AF. Clinical practice. Hypercalcemia associated with cancer. N Engl J Med 2005;352:373-379. https://doi.org/10.1056/NEJMcp042806
  4. Burtis WJ, Brady TG, Orloff JJ, Ersbak JB, Warrell RP Jr, Olson BR, et al. Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer. N Engl J Med 1990;322:1106-1112. https://doi.org/10.1056/NEJM199004193221603
  5. Monno S, Nagata A, Furuta S. Hypercalcemia of cancer in the digestive tract. J Clin Gastroenterol 1987;9:78-82. https://doi.org/10.1097/00004836-198702000-00020
  6. Nakayama K, Fukumoto S, Takeda S, Takeuchi Y, Ishikawa T, Miura M, et al. Differences in bone and vitamin D metabolism between primary hyperparathyroidism and malignancy-associated hypercalcemia. J Clin Endocrinol Metab 1996;81:607-611.
  7. Horwitz MJ, Tedesco MB, Sereika SM, Hollis BW, Garcia-Ocana A, Stewart AF. Direct comparison of sustained infusion of human parathyroid hormone-related protein-(1-36) [hPTHrP-(1-36)] versus hPTH-(1-34) on serum calcium, plasma 1,25-dihydroxyvitamin D concentrations, and fractional calcium excretion in healthy human volunteers. J Clin Endocrinol Metab 2003;88:1603-1609. https://doi.org/10.1210/jc.2002-020773
  8. Nakajima K, Tamai M, Okaniwa S, Nakamura Y, Kobayashi M, Niwa T, et al. Humoral hypercalcemia associated with gastric carcinoma secreting parathyroid hormone: a case report and review of the literature. Endocr J 2013;60:557-562. https://doi.org/10.1507/endocrj.EJ12-0406
  9. Truong NU, deB Edwardes MD, Papavasiliou V, Goltzman D, Kremer R. Parathyroid hormone-related peptide and survival of patients with cancer and hypercalcemia. Am J Med 2003;115:115-121. https://doi.org/10.1016/S0002-9343(03)00310-3
  10. Engelich G, Swan N, Hartshorn KL. Raised plasma parathyroid hormone related peptide in gastric adenocarcinoma. J Clin Pathol 2000;53:643-644. https://doi.org/10.1136/jcp.53.8.643
  11. Alipov GK, Ito M, Nakashima M, Ikeda Y, Nakayama T, Ohtsuru A, et al. Expression of parathyroid hormone-related peptide (PTHrP) in gastric tumours. J Pathol 1997;182:174-179. https://doi.org/10.1002/(SICI)1096-9896(199706)182:2<174::AID-PATH840>3.0.CO;2-4
  12. Deans C, Wigmore S, Paterson-Brown S, Black J, Ross J, Fearon KC. Serum parathyroid hormone-related peptide is associated with systemic inflammation and adverse prognosis in gastroesophageal carcinoma. Cancer 2005;103:1810-1818. https://doi.org/10.1002/cncr.20972
  13. Abdeen O, Pandol SJ, Burton DW, Deftos LJ. Parathyroid hormone-related protein expression in human gastric adenocarcinomas not associated with hypercalcemia. Am J Gastroenterol 1995;90:1864-1867.

Cited by

  1. Prognostic factors for survival in patients with gastric adenocarcinoma vol.4, pp.1, 2016, https://doi.org/10.1002/cnr2.1305